Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11, Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-15

  Fournier, Patrick ^a   Dumulon Perreault, Véronique ^a   Ait Mohand, Samia ^a   Langlois, Réjean ^a   Bénard, François ^b   Lecomte, Roger ^a   Guérin, Brigitte ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Bombesin; Gastrin releasing peptide receptors; Homo dimer; PET imaging

Indexed keywords

BOMBESIN; COPPER 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID POLYETHYLENE GLYCOL BOMBESIN (6-14) CU 64; COPPER BOMBESIN (6-14) POLYETHYLENE GLYCOL LYSINE 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID GLYCINE BOMBESIN (6-14) CU 64; COPPER BOMBESIN (6-14) POLYETHYLENE GLYCOL LYSINE 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID POLYETHYLENE GLYCOL GLYCINE BOMBESIN (6-14) CU 64; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL KINETICS; CELL TRANSPORT; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY CLEARANCE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN STABILITY; RADIATION DOSE DISTRIBUTION;

EID: 84872611638     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-8     Document Type: Article

References (40)

1. Mantey S, Frucht H, Coy DH, Jensen RT: Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes. Mol Pharmacol 1993, 43:762-774.
2. Yegen BC: Bombesin-like peptides: candidates as diagnostic and therapeutic tools. Curr Pharm Des 2003, 9:1013-1022.
3. Moody TW, Bertness V, Carney DN: Bombesin-like peptides and receptors in human tumor cell lines. Peptides 1983, 4:683-686.
4. Reile H, Armatis PE, Schally AV: Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994, 25:29-38.
5. Markwalder R, Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research 1999, 59:1152-1159.
6. Pagani A, Papotti M, Sanfilippo B, Bussolati G: Expression of the gastrinreleasing peptide gene in carcinomas of the breast. Int J Cancer 1991, 47:371-375.
7. Halmos G, Wittliff JL, Schally AV: Characterization of bombesin/gastrinreleasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Research 1995, 55:280-287.
8. Gugger M, Reubi JC: Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast. Am J Pathol 1999, 155:2067-2076.
9. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M: Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)] bombesin(6-14). Cli Cancer Res 2002, 8:1139-1146.
10. Albrecht M, Doroszewicz J, Gillen S, Gomes I, Wilhelm B, Stief T, Aumüller G: Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate 2004, 58:82-94.
11. Aprikian AG, Tremblay L, Han K, Chevalier S: Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997, 72:498-504.
12. Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, Fuse H, Saiki I: Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Letters 1998, 133:27-33.
13. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989, 63:1714-1720.
14. Festuccia C, Angelucci A, Gravina G, Eleuterio E, Vicentini C, Bologna M: Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement. Exp Cell Res 2002, 280:1-11.
15. Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K: Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncologica 2002, 41:289-296.
16. Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M: In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 1998, 75:418-431.
17. Anastasi A, Erspamer V, Bucci M: Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971, 27:166-167.
18. Delle Fave G, Annibale B, De Magistris L, Severi C, Bruzzone R, Puoti M, Melchiorri P, Torsoli A, Erspamer V: Bombesin effects on human GI fonctions. Peptides 1985, 6:113-116.
19. Martinez V, Tache Y: Bombesin in the brain-gut axis. Peptides 2000, 21:1617-1625.
20. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, Donohue PJ, Weber HC, Sainz E, Battey JF, Coy DH: Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 1998, 343:275-287.
21. Schuhmacher J, Zhang H, Doll J, Maecke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M: GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog. J Nucl Med 2005, 46:691-699.
22. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS: MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004, 45:1390-1397.
23. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, Hoffman TJ, Sieckman GL, Figueroa SD, Smith CJ: [64Cu-NOTA-8-Aoc-BBN (7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 2007, 104:12462-12467.
24. Lane SR, Nanda P, Rold TL, Sieckman GL, Figueroa SD, Hoffman TJ, Jurisson SS, Smith CJ: Optimization, biological evaluation and microPET imaging of xenografted mouse model. Nucl Med Biol 2010, 37:751-761.
25. Yan Y, Chen X: Peptide heterodimers for molecular imaging. Amino Acids 2011, 41:1081-1092.
26. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ: Hitting multiple targets with multimeric ligands. Exp Opin Ther Targets 2004, 8:565-586.
27. Carrithers MD, Lerner MR: Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem Biol 1996, 3:537-542.
28. Gawlak SL, Kiener PA, Braslawsky GR, Greenfield RS: Homodimeric forms of bombesin act as potent antagonist of bombesin on swiss 3T3 cells. Growth Factor 1991, 5:159-170.
29. Abiraj K, Jaccard H, Kretzschmar M, Helm L, Maecke HR: Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric analogues for multimodality tumor imaging and therapy. Chem Commun 2008, 28:3248-3250.
30. Williams HA, Robinson S, Julyan P, Zweit J, Hastings D: A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Mol Imaging 2005, 32:1473-1480.
31. Guérin B, Ait-Mohand S, Tremblay M-C, Dumulon-Perreault V, Fournier P, Bénard F: Total solid-Phase synthesis of NOTA-functionalized peptides for PET or SPECT imaging. Org Lett 2010, 12:280-283.
32. Cheng Y, Prusoff WH: Relationship between the inhibition constant ([Ki]) and the concentration of inhibitor which causes 50 per cent inhibition ([I50]) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
33. Zeisler SK, Pavan RA, Orzechowski J, Langlois R, Rodrigue S, van Lier JE: Production of 64Cu on the Sherbrooke TR-PET cyclotron. J Radioanal Nucl Chem 2003, 257:175-177.
34. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ: Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997, 24:35-43.
35. Ait-Mohand S, Fournier P, Dumulon-Perreault V, Keifer GE, Jurek P, Ferreira CL, Bénard F, Guérin B: Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjugate Chem 2011, 22:1729-1735.
36. Selivanov V, Picard Y, Cadorette J, Rodrigue S, Lecomte R: Detector response models for statistical iterative image reconstruction in high resolution PET. IEEE T Nucl Sci 2000, 47:1168-1175.
37. Liu S: Radiolabeled cyclic RGD peptides as Integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem 2009, 20:2199-2213.
38. Behr TM, Goldenberg DM, Becker W: Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998, 25:201-212.
39. Conklin BR, Bourne HR: Structural elements of Gα subunits that interact with Gβγ, receptors and effectors. Cell 1993, 73:631-641.
40. IUPAC-IUB Joint Commission on Biochemical Nomenclature: Nomenclature and symbolism for amino acids and peptides. Eur J Biochem 1984, 138:9-37.